Cholangiocarcinoma Diagnosis Mistakes That Can Cost Patients Their Best Chance

What Are The Most Common Cholangiocarcinoma Diagnosis Mistakes?

After a cholangiocarcinoma diagnosis, the danger is not only the cancer. The danger is drift. Drift happens when patients wait between scans, appointments, referrals, pathology reviews, and treatment decisions without a clear response plan.

In cholangiocarcinoma, time matters because options can narrow quickly. The goal is not to panic. The goal is to move in the right order, with the right information, before opportunities are missed.

The most common cholangiocarcinoma diagnosis mistakes include:

• Assuming every cancer team has deep cholangiocarcinoma experience.
• Accepting “not operable” without another expert surgical opinion.
• Delaying hepatobiliary surgical review.
• Not confirming pathology, subtype, and tumour biology.
• Delaying comprehensive genomic profiling.
• Letting the case drift between tests, scans, and appointments.
• Not keeping a complete patient record from day one.
• Leaving the caregiver outside the decision-making process.

Mistake 1: Assuming All Cancer Teams Have Cholangiocarcinoma Experience

Cholangiocarcinoma, also known as bile duct cancer, is rare and complex. Not every oncologist, surgeon, radiologist, or hospital team sees enough cases to recognise every option early.

This matters because cholangiocarcinoma treatment is not one straight road. Surgery, chemotherapy, immunotherapy, targeted therapy, radiation, liver-directed treatment, clinical trials, and supportive care may all become relevant depending on the patient’s disease stage, tumour location, biology, and response.

Patient action: Ask directly whether your case has been reviewed by a team with current cholangiocarcinoma experience.

Useful questions to ask:

• How many cholangiocarcinoma patients does this team treat each year?
• Has my case been reviewed by a hepatobiliary surgeon?
• Has my case been discussed in a multidisciplinary team meeting?
• Should I seek a second opinion from a cholangiocarcinoma-experienced centre?

Mistake 2: Accepting “Not Operable” Without Another Surgical Opinion

“Not operable” is an opinion, not an endpoint.

Surgery is one of the most important potential curative pathways in cholangiocarcinoma. Many patients are told they are not surgical candidates. Sometimes that is correct. Sometimes it reflects the experience, risk appetite, resources, or interpretation of one team.

The better question is not only: “Can I have surgery?”

The better question is: “What would need to change to make surgery possible. What would I need to do?”

Patient action: If surgery has been ruled out, ask for your scans and reports to be available so you can have them reviewed by an independent high-volume hepatobiliary surgeon with current cholangiocarcinoma experience.

Useful questions to ask:

• Why exactly is surgery not possible at this point?
• Is the issue tumour location, vascular involvement, liver reserve, spread, performance status, or something else?
• Could treatment shrink or control the disease enough to reconsider surgery later?
• Do you have a problem with me seeking an independent second hepatobiliary surgical opinion?

Mistake 3: Delaying A Hepatobiliary Surgical Review

Cholangiocarcinoma sits in a difficult anatomical area. The bile ducts, liver, gallbladder, pancreas, blood vessels, and digestive system are closely connected. This is why early review by a hepatobiliary surgeon can matter, even when surgery seems unlikely.

A surgeon may identify whether the disease is clearly unresectable, borderline, technically complex, or potentially convertible after treatment. Without that review, a patient may move into treatment without a full understanding of whether surgery was ever possible.

Patient action: Do not wait until after several treatment cycles to ask whether a hepatobiliary surgeon has reviewed your case. Ask early.

Useful questions to ask:

• Has a hepatobiliary surgeon reviewed my imaging?
• Is my tumour intrahepatic, perihilar, distal extrahepatic, gallbladder-related, or uncertain?
• Is my case clearly unresectable, borderline, or potentially operable?
• Should my scans be reviewed at a specialist liver and bile duct cancer centre?

Mistake 4: Not Confirming Pathology And Tumour Biology

Pathology is not just a label. It is the first map of the disease.

A pathology report may show where the cancer appears to come from, what type of cells are involved, how aggressive the tumour looks, and which markers are present or absent. This helps guide treatment decisions and may also identify whether more testing is needed.

Often referred as an IHC report. Immunohistochemical. Laboratory applies dyes to stain the sample. Each different colour that illuminates is associated to known biomarkers common in Cholangiocarcinoma’s.

Patient action: Request a full digital copy of the pathology report, not only a verbal summary. Digital copy provides you the freedom to share with your team, and especially second opinion situations.

Important markers and details to ask about may include:

• Diagnosis and tumour type.
• Primary site of origin, ie;
• Intrahepatic, perihilar, distal extrahepatic, or uncertain subtype.
• Tumour Characteristics – differentiation; Poor, moderate or well defined.
• CK7, CK19, CK20, CDX2, SATB2, TTF-1, PAX8, GATA3, or other markers that confirm Cholangiocarcinoma.
• MMR status: MLH1, PMS2, MSH2, MSH6.
• MSI status.
• PD-L1.
• HER2.
• TMB, if tested.

These markers do not all mean the same thing. Some help confirm the cancer type. Some may affect treatment or trial pathways. Some may show whether immunotherapy or targeted therapy should be explored. It is very important that all are requested, recorded, and you retain a personal digital copy no file.

Mistake 5: Delaying Genomic Profiling

Genomic profiling should not be treated as something to consider only after every standard option has failed.

In cholangiocarcinoma, genomic profiling may identify mutations, fusions, or biomarkers that can influence treatment planning, second-line options, clinical trial matching, and sometimes immunotherapy or targeted therapy pathways.

Patient action: Ask early whether comprehensive genomic profiling has been ordered, what tissue will be used, and when the result is expected.

Important genomic or biomarker areas to ask about may include:

• IDH1
• FGFR2 fusions or rearrangements
• BRAF
• HER2
• NTRK
• RET
• KRAS
• BRCA1 / BRCA2 or other DNA repair genes
• MSI-High
• dMMR
• TMB-High

If tissue is limited, timing matters. If genomic testing is delayed, treatment options or clinical trial options may also be delayed.

Useful questions to ask:

• Has comprehensive genomic profiling been ordered?
• Is there enough tissue available for testing?
• What laboratory is doing the test?
• When will the result be available?
• Who will explain the result to me in plain language?
• Could the result change my treatment pathway or clinical trial options?

Mistake 6: Letting The Case Drift Between Tests, Scans, And Appointments

Drift is where options are lost.

Drift is the quiet time between decisions. Waiting for one result. Waiting for one appointment. Waiting for someone else to connect the next step. In a fast-moving cancer, the patient and caregiver need to know what is pending, who owns the next action, and when the next decision will be made.

Patient action: Track every pending result, referral, scan, test, and decision point.

Useful questions to ask:

• What are we waiting for right now?
• Who is responsible for the next step?
• When should I expect the result or appointment?
• What happens if this result is delayed?
• What is the next treatment decision?
• What options are being preserved while we wait?

Mistake 7: Not Keeping A Patient Record From Day One

A cholangiocarcinoma diagnosis creates a flood of information. Scans, blood tests, pathology, genomic reports, treatment plans, hospital notes, medications, symptoms, side effects, and appointments can quickly become overwhelming.

Without a clear record, patients and caregivers may struggle to explain the case, seek second opinions, track changes, or notice what has not yet been done.

Patient action: Start a patient record from day one.

Keep copies of:

• Pathology reports.
• Imaging reports.
• Blood test results.
• Operation reports, if relevant.
• Discharge summaries.
• Genomic profiling reports.
• Medication lists.
• Treatment plans.
• Questions for appointments.
• Notes from each medical discussion.

This is not paperwork for the sake of paperwork. It is survival organisation. It helps the patient and caregiver stay oriented when the system becomes fragmented.

Mistake 8: Leaving The Caregiver Outside The Decision-Making Process

The patient is often tired, shocked, unwell, and overloaded. A caregiver can hear what the patient misses, ask the question the patient forgets, and help keep the plan moving.

In cholangiocarcinoma, the caregiver is not just emotional support. The caregiver can become the patient’s second brain, record keeper, question tracker, appointment organiser, and response partner.

Patient action: Bring a caregiver, family member, or trusted support person into the process early.

Useful caregiver roles include:

• Taking notes during appointments.
• Tracking results and referrals.
• Keeping copies of reports.
• Asking follow-up questions.
• Helping the patient compare options.
• Watching for delays or missed steps.

Cholangiocarcinoma Diagnosis Checklist For Patients And Caregivers

This checklist is designed to reduce confusion and help patients know what to ask early.

• Ask whether your case has been reviewed by a cholangiocarcinoma-experienced oncologist.
• Ask whether a hepatobiliary surgeon has reviewed your scans.
• Ask whether you need a second or third surgical opinion.
• Request digital copies of pathology, imaging, blood tests, MDT notes, and discharge summaries.
• Confirm whether your tumour subtype has been clearly identified.
• Confirm MMR, MSI, HER2, PD-L1, TMB, FGFR2, IDH1, BRAF, NTRK, KRAS, and other relevant markers where appropriate.
• Ask whether comprehensive genomic profiling has been ordered.
• Ask what treatment options exist now, next, and if the current treatment fails.
• Ask whether any clinical trials match your tumour biology.
• Ask what decision needs to be made next.
• Ask what could be lost if there is a delay.
• Record every question, result, appointment, and decision.

What Should Patients Do Instead?

The best response after a cholangiocarcinoma diagnosis is not to wait passively for the system to carry every next step. The best response is to become organised early.

Patients and caregivers should aim to:

• Understand the diagnosis in plain language.
• Know the tumour location and subtype.
• Confirm whether surgery has been properly reviewed.
• Request pathology and genomic testing early.
• Seek specialist cholangiocarcinoma input.
• Preserve records and reports.
• Ask what options are available now and what options may become available later.
• Track the next step, the next decision, and the next risk.

The aim is not to become a doctor. The aim is to become an informed patient who can recognise the next important question.

Why These Mistakes Matter

These mistakes matter because cholangiocarcinoma is not only a cancer problem. It is also a time, information, and sequencing problem.

Patients often lose options before they know those options existed. A missed surgical review, delayed genomic test, incomplete pathology understanding, or slow referral can change the pathway.

Think of the diagnosis like arriving at a junction in heavy fog. The road forward may exist, but it can only be seen if the right lights are turned on early. Specialist review, tumour biology, genomic profiling, second opinions, and organised records are those lights.

The goal is simple: understand earlier, respond earlier, and keep options open while they still exist.

Start With The Patient Response System

Cholangiocarcinoma Foundation Australia exists to help patients and caregivers move from confusion to structured response.

If you or someone you love has been newly diagnosed with cholangiocarcinoma or bile duct cancer, start with the next practical step.

• Newly Diagnosed With Cholangiocarcinoma
• Clinical Trials
• Patient Navigator Journal
• Find A Specialist
• Second Opinion Support

Follow the process. Avoid mistakes. Keep options open.